Industry News

• NIH to investigate minor cannabinoids and terpenes for potential pain-relieving properties  Nine new NIH research awards totaling $3 million will investigate the potential pain-relieving properties and mechanisms of actions of the diverse phytochemicals in cannabis, including both minor cannabinoids and terpenes. These awards will identify any potential roles in pain management.
  September 19, 2019  
• ALS gene may be a hitchhiker’s guide to the neuron  Scientists have peered inside neurons and watched the workings of annexin A11, a gene linked to ALS. They found the neurons use the gene to ship housekeeping instructions via a newly discovered “hitchhiking” system tie up deliveries at the cell’s loading docks. The study was published in Cell.
  September 19, 2019  
• NIH awards $20 million over five years to bring together music therapy and neuroscience  The NIH has awarded $20 million over five years to support the first research projects of the Sound Health initiative to explore the potential of music for treating a wide range of conditions resulting from neurological and other disorders.
  September 19, 2019  
• MannKind reports positive Afrezza® clinical data from Type 1 diabetes study  MannKind Corp. announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder. MannKind investigators reported data1 from more than 500 patients with type 1 diabetes comparing Afrezza to rapid-acting injected insulin analog (insulin aspart) therapy to assess glucose control.
  September 19, 2019  
• AveXis reports new data continuing to show significant therapeutic benefit of Zolgensma®   AveXis, a Novartis company, announced that new interim data from the Phase 3 SPR1NT trial in pre-symptomatic patients as well as interim data from the ongoing Phase 3 STR1VE clinical program for Zolgensma® (onasemnogene abeparvovec-xioi) showed positive outcomes in patients with SMA Type 1.
  September 19, 2019  
• Aerie Pharma submits prior approval supplement to FDA to allow production of Rocklatan®   Aerie Pharmaceuticals announced the submission of a prior approval supplement to the FDA. If approved, the PAS will permit production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the U.S. in Aerie’s new manufacturing plant in Athlone, Ireland.
  September 19, 2019  
• DoD awards $6.42M to Roswell Park Comprehensive Cancer Center   AIM ImmunoTech announced the U.S. DOD)has granted a four-year, $6.42 million "Breakthrough Award" to Roswell Park Comprehensive Cancer Center for a clinical study of a combination of therapies, including the company's drug Ampligen, in patients with brain-metastatic breast cancer.
  September 19, 2019  
• Trovagene announces successful completion of phase 1b trial of onvansertib in AML  Trovagene announced successful completion of its Phase 1b trial of onvansertib in combination with standard-of-care chemotherapy in acute myeloid leukemia and initiation of patient enrollment in Phase 2. The Phase 1b dose-escalation trial confirmed that onvansertib is safe and well tolerated.
  September 19, 2019  
• VBI Vaccines announces pricing of $35 million public offering  VBI Vaccines announced pricing of its previously announced underwritten public offering of 70,000,000 common shares, at a public offering price of US$0.50 per share. VBI also granted the underwriters a 30-day option to purchase up to an additional 10,500,000 common shares at US$0.50 per share.
  September 19, 2019  
• Lineage Cell Therapeutics receives CE Mark approval for Renevia®  Lineage Cell Therapeutics announced that Renevia®, the Company’s facial aesthetics product, has been granted a CE Mark. Renevia received a Class III classification with an intended use in adults as a resorbable matrix for delivery of autologous adipose tissue preparations.
  September 19, 2019  

   (next 10 articles)